IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.51
+0.36 (+3.23%)
At close: 4:00PM EDT

11.51 0.00 (0.00%)
After hours: 4:39PM EDT

Stock chart is not supported by your current browser
Previous Close11.15
Open11.20
Bid11.11 x 4000
Ask11.52 x 800
Day's Range11.11 - 11.64
52 Week Range7.60 - 17.76
Volume1,250,114
Avg. Volume1,517,161
Market Cap1.791B
Beta (3Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-1.94
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.45
Trade prices are not sourced from all markets
  • Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today
    Motley Fool4 days ago

    Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today

    An SEC filing shows an activist investor is building a sizable position in the company.

  • 6 Positions the Vanguard Health Care Fund Continues to Increase
    GuruFocus.com5 days ago

    6 Positions the Vanguard Health Care Fund Continues to Increase

    CVS Health tops the list

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of IRWD earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Ironwood Pharmaceuticals Inc Earnings Call

  • Business Wire13 days ago

    Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019

    – IW-3718 Phase II data in patients with persistent GERD to be featured in oral presentation –

  • Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%?
    Simply Wall St.13 days ago

    Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors can approximate the average market return by buying an index fund. While individual st...

  • Business Wire14 days ago

    Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the 2019 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 14, 2019 at 8:00 a.m. Pacific Time at The Encore Hotel in Las Vegas. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required.

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWDView full report here! Summary * Bearish sentiment is moderate and increasing * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on April 9. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.08 billion over the last one-month into ETFs that hold IRWD are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall
    Zacks19 days ago

    Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall

    Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.

  • Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript
    Motley Fool19 days ago

    Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript

    IRWD earnings call for the period ending March 31, 2019.

  • Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ?
    Insider Monkey19 days ago

    Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

  • Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
    Zacks20 days ago

    Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

    Ironwood (IRWD) delivered earnings and revenue surprises of -62.50% and -17.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press20 days ago

    Ironwood: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 38 cents per share. Losses, adjusted for non-recurring costs and restructuring costs, came to 26 cents per share. The results missed Wall ...

  • Business Wire20 days ago

    Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance

    – Ironwood launches as GI-focused healthcare company following separation of Cyclerion Therapeutics on April 1, 2019 –

  • Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks26 days ago

    Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wirelast month

    Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced it will host its first quarter 2019 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 2, 2019. Individuals interested in participating in the call should dial (866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international) using conference ID number 8429338. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

  • Business Wirelast month

    Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced an adjustment to the conversion rate applicable to its existing 2.25% Convertible Senior Notes due 2022, effective April 15, 2019. The adjustment was effected pursuant to the indenture, dated as of June 15, 2015, and as supplemented April 5, 2019, between Ironwood and U.S. Bank National Association, as trustee, pursuant to which the Convertible Notes were originally issued. In connection with the separation of Ironwood and Cyclerion Therapeutics, Inc. (Cyclerion) into two independent, publicly traded companies, on April 1, 2019, Ironwood distributed to its shareholders one share of Cyclerion common stock for every 10 shares of Ironwood common stock held as of the close of business on March 19, 2019, the record date for the distribution.

  • Will Ironwood Suffer From Dependence on Linzess' Progress?
    Zacks2 months ago

    Will Ironwood Suffer From Dependence on Linzess' Progress?

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.

  • As Ironwood spinout Cyclerion launches on the Nasdaq, CEO Hecht sees 'a fresh start'
    American City Business Journals2 months ago

    As Ironwood spinout Cyclerion launches on the Nasdaq, CEO Hecht sees 'a fresh start'

    "To be clear, this is not a division between commercial and R-and-D priorities," new Cyclerion CEO Pete Hecht said of the split between the company he founded, Ironwood Pharmaceuticals, and his new firm.

  • Business Wire2 months ago

    Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion Therapeutics, Inc. (Cyclerion). Ironwood is executing on its strategy to drive growth as a GI-focused company, building upon its commercial success with LINZESS and advancing its late-stage, first-in-category development candidates including IW-3718 for the potential treatment of persistent gastroesophageal reflux disease (GERD) and MD-7246 for the potential treatment of abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D).

  • Ironwood's new CEO has big plans for Linzess, but is mum on R&D
    American City Business Journals2 months ago

    Ironwood's new CEO has big plans for Linzess, but is mum on R&D

    With the three original founders leaving for new company Cyclerion, as well as Ironwood's longtime Head of R&D; Mark Currie, will Ironwood's innovation peter out?

  • Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares
    Simply Wall St.2 months ago

    Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...

  • Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?

    Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement
    Business Wire2 months ago

    Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc. (Cyclerion) has been declared effective by the U.S. Securities and Exchange Commission (SEC). The Form 10 reflects Ironwood’s plan for a tax-free spin-off of Cyclerion as a publicly-traded company, which is expected to be completed on April 1, 2019. The completion of the separation is set to occur through a distribution to Ironwood shareholders of one share of Cyclerion common stock for every 10 shares of Ironwood common stock held as of the close of business on March 19, 2019, the record date for the distribution.

  • Business Wire2 months ago

    Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 14, 2019 at 2:35 p.m. Eastern Time at The Loews Miami Beach Hotel in Miami. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

  • Business Wire3 months ago

    Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the 39th Annual Cowen Health Care Conference on Monday, March 11, 2019 at 4:10 p.m. Eastern Time at The Boston Marriott Copley Place in Boston. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.